Skip to main content
. Author manuscript; available in PMC: 2014 Feb 21.
Published in final edited form as: Leuk Lymphoma. 2012 Sep 28;54(4):683–687. doi: 10.3109/10428194.2012.728597

Figure 1.

Figure 1

Schematic model of CRBN E3 ubiquitin ligase in thalidomide-induced teratogenicity. Thalidomide binds to CRBN and inhibits its associated E3 ubiquitin ligase activity. This inhibition results in unknown substrates accumulating and eventually cause developmental defects, partially via downregulation of FGF8 (Ito, et al, 2010).